Skip to main content
SpringerLink
Log in

Spender T-Zellen kontrolliert lenken

Graft-versus-Leukämie Effekt nach allogener hämatopoetischer Stammzelltransplantation

  • onkologie
  • Published:
Wiener klinisches Magazin Aims and scope

Zusammenfassung

Die allogene hämatopoetische Stammzelltransplantation (HSZT) ist die einzige kurative Behandlungsoption für viele Patienten mit ausgewählten malignen hämatologischen Erkrankungen als auch mit lebensbedrohlichen genetischen und hämatologischen Erkrankungen einschließlich erworbener schwerer Knochenmarkschädigung und angeborenen Immundysfunktionen (1).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Baron F, Storb R. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Semin Immunopathol. 2004;26:71–94.

    Article  PubMed  Google Scholar 

  2. Riddell SR, Berger C, Murata M, et al. The graft versus leukaemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev. 2003;17:153–62.

    Article  PubMed  Google Scholar 

  3. Kolb HJ, Schmidt C, Barrett AJ, et al. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103:767–76.

    Article  PubMed  CAS  Google Scholar 

  4. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–2100.

    Article  PubMed  CAS  Google Scholar 

  5. Falkenburg JH, Warren EH. Graft versus leukaemia reactivity after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:S33–8.

    Article  PubMed  Google Scholar 

  6. Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet. 2009;373:1550–61.

    Article  PubMed  CAS  Google Scholar 

  7. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.

    PubMed  CAS  Google Scholar 

  8. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2005;11:945–56.

    Article  PubMed  Google Scholar 

  9. Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117:3214–9.

    Article  PubMed  CAS  Google Scholar 

  10. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med. 1979;300:1068–73.

    Article  PubMed  CAS  Google Scholar 

  11. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med. 1988;108:806–14.

    Article  PubMed  CAS  Google Scholar 

  12. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–62.

    PubMed  CAS  Google Scholar 

  13. Kuzmina Z, Eder S, Böhm A, et al. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia. 2012;26:746–56.

    Article  PubMed  CAS  Google Scholar 

  14. Thepot S, Zhou J, Perrot A, et al. The graft-versus-leukemia effect is mainly restricted to NIH-defned chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia. 2010;24:1852–8.

    Article  PubMed  CAS  Google Scholar 

  15. Inamoto Y, Flowers MED, Lee SJ, et al. Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood. 2011;118:456–63.

    Article  PubMed  CAS  Google Scholar 

  16. Prinz E, Keil F, Mitterbauer M, et al. Successful immunotherapy in early relapse of acute myeloid leukemia after nonmyeloablative allogeneic stem cell transplantation. Ann Hematol. 2003;82:295–8.

    PubMed  CAS  Google Scholar 

  17. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy for relapsed leukaemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol. 1995;23:1553–62.

    PubMed  CAS  Google Scholar 

  18. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433–44.

    PubMed  Google Scholar 

  19. Dazzi F, Szydlo RM, Craddock C, et al. Comparison of single-dose and escalating dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukaemia. Blood. 2000;95:67–71.

    PubMed  CAS  Google Scholar 

  20. Greinix HT. DLI or second transplant. Ann Hematol. 2002;81(Suppl 2):34–5.

    Google Scholar 

  21. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390–3400.

    Article  PubMed  CAS  Google Scholar 

  22. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marror transplantation with lethal cyto-reduction for the treatment of malignant and non-malignant hematologic diseases. Blood. 1998;91:756–63

    PubMed  CAS  Google Scholar 

  23. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2006;24:444–53.

    Article  PubMed  CAS  Google Scholar 

  24. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006;108:1092–9.

    Article  PubMed  CAS  Google Scholar 

  25. Mitterbauer G, Nemeth P, Wacha S, et al. Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction. Brit J Haematol. 1999;106:634–43.

    Article  CAS  Google Scholar 

  26. Falkenburg JH, Willemze R. Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia. Best Pract Res Clin Haematol. 2004;17:415–25.

    Article  PubMed  CAS  Google Scholar 

  27. Warren EH, Fujii N, Akatsuka Y, et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood. 2010;115:3869–78.

    Article  PubMed  CAS  Google Scholar 

  28. Casucci M, Bondanza A, Falcone L, et al. Genetic engineering of T cells for the immunotherapy of haematological malignancies. Tissue Antigens. 2012;79:4–14.

    Article  PubMed  CAS  Google Scholar 

  29. Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I–II study. Lancet Oncol. 2009;10:489–500.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Universität Wien, Klinik für Innere Medizin I, Knochenmarktransplantation, Währinger Gürtel 18-20, 1090, Wien, Deutschland

    Hildegard T. Greinix &  Zoya Kuzmina

  2. Medizinische Universität Wien, Klinik für Blutgruppenserologie und Transfusionsmedizin, Wien, Deutschland

    Nina Worel

Authors
  1. Hildegard T. Greinix
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zoya Kuzmina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nina Worel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hildegard T. Greinix.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Greinix, H.T., Kuzmina, Z. & Worel, N. Spender T-Zellen kontrolliert lenken. Wien klin Mag 15, 22–26 (2012). https://doi.org/10.1007/s00740-012-0062-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00740-012-0062-7

Search

Navigation